AVBP

News ArriVent Posts Wider Loss in Fiscal Q2

14d ago

SEC filing AVBP Announces Firmonertinib Phase 3 Data, ARR-002 Dual-Target ADC Preclinical Success, AACR 2026 Presentations

77d ago

SEC filing AVBP Reports $312.8M Cash, $312.8M Investments, Firmonertinib Phase 3 Data Mid‑2026, ADC ARR‑217 Phase 1, NMPA Approval China

89d ago

Insider trade Sale by HILLHOUSE INVESTMENT MANAGEMENT, LTD. / HHLR ADVISORS, LTD.

104d ago

News $207B Market Shift: The Race for Fast Track Approval in Oncology

117d ago